The Performance of Multi-tracer Multimodality PET in Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05004961

Enrollment

200

Registered

2021-08-13

Start date

2019-09-15

Completion date

2023-12-31

Last updated

2023-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Positron-Emission Tomography

Keywords

Positron-Emission Tomography, Lymphoma

Brief summary

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

Detailed description

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 80 Years

Healthy volunteers

Inclusion criteria

* pathologically diagnosed as lymphoma; * Written informed consent for receiving FAPI-04 PET examinations. * cancer planned chemotherapy or immunotherapy scheme. * expected survival ≥ 12 weeks

Exclusion criteria

* cannot lie supine for half an hour; * refuse to join the clinical researcher; * severe liver or kidney dysfunction * pregnancy or lactation

Design outcomes

Primary

Measure	Time frame	Description
SUVmax	150 days	Standardized uptake value of 68Ga/ 18F-NOTA-FAPI 04 for target lesion of subject or suspected tumor in each time point window (SUV)

Countries

China

Contacts

Primary ContactXuejuan Wang, MD

xuejuan_wang@hotmail.com86 010 88196363

Outcome results